Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT [Yahoo! Finance]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Yahoo! Finance
analyst Matthew Biegler maintained a Buy rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) and set a $7 price target. However, J.P. Morgan analyst Anupam Rama reiterated a Hold rating on the stock on October 23 without assigning a price target. Rama based the rating on the future potential and current status of CytomX Therapeutics' CX-2051, stating that he expects more clarity on its safety profile and efficacy from the upcoming Phase 1 data update for CX-2051 in advanced colorectal cancer. Although the initial data exhibited promising efficacy with a higher objective response rate when compared to standard treatments, the analyst believes that concerns remain about adverse events, especially diarrhea. This could affect the overall safety perception of the drug, supporting the cautious stance. CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage, oncology-focused biopharmaceutical company that develops conditionally activated biologics localized to the tumor microenviro
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics to Present at Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics to Present at Upcoming December Investor ConferencesGlobeNewswire
- Why Analysts Say the CytomX Story Is Evolving After Recent Clinical Momentum and Price Target Hike [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics: Leaning Into The Hype, But What's Next? [Seeking Alpha]Seeking Alpha
- CytomX Therapeutics to Present at the Jefferies London Healthcare ConferenceGlobeNewswire
CTMX
Earnings
- 11/6/25 - Miss
CTMX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CTMX's page on the SEC website